UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
34.54
+0.16 (0.47%)
At close: Jun 26, 2026, 4:00 PM EDT
34.10
-0.44 (-1.27%)
After-hours: Jun 26, 2026, 7:02 PM EDT
UroGen Pharma Revenue
UroGen Pharma had revenue of $50.96M in the quarter ending March 31, 2026, with 151.60% growth. This brings the company's revenue in the last twelve months to $140.49M, up 52.92% year-over-year. In the year 2025, UroGen Pharma had annual revenue of $109.79M with 21.45% growth.
Revenue (ttm)
$140.49M
Revenue Growth
+52.92%
P/S Ratio
11.98
Revenue / Employee
$471,453
Employees
298
Market Cap
1.68B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 109.79M | 19.39M | 21.45% |
| Dec 31, 2024 | 90.40M | 7.69M | 9.29% |
| Dec 31, 2023 | 82.71M | 18.36M | 28.52% |
| Dec 31, 2022 | 64.36M | 16.32M | 33.96% |
| Dec 31, 2021 | 48.04M | 36.24M | 307.17% |
| Dec 31, 2020 | 11.80M | 11.78M | 65,450.00% |
| Dec 31, 2019 | 18.00K | -1.11M | -98.40% |
| Dec 31, 2018 | 1.13M | -7.03M | -86.17% |
| Dec 31, 2017 | 8.16M | -9.37M | -53.46% |
| Dec 31, 2016 | 17.53M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Fortrea Holdings | 2.71B |
| Sarepta Therapeutics | 2.18B |
| Innoviva | 420.69M |
| Maravai LifeSciences Holdings | 204.73M |
| Zymeworks | 81.26M |
| Septerna | 72.26M |
| Vir Biotechnology | 65.50M |
| Mesoblast | 65.38M |
URGN News
- 6 days ago - UroGen Pharma Transcript: AGM 2026 - Transcripts
- 18 days ago - UroGen Pharma Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 23 days ago - UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 26 days ago - UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution - GlobeNewsWire
- 26 days ago - UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference - GlobeNewsWire
- 4 weeks ago - UroGen Pharma Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA - Transcripts
- 5 weeks ago - UroGen Pharma Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference - Transcripts
- 6 weeks ago - UroGen Pharma reports month results from UTOPIA trial - TheFly